The increasing prevalence of urinary tract infection (UTI) and growth in the number of prescription of quinolones antibiotics is expected to fuel the growth of the urinary tract infection treatment market. According to a new study published by Future Market Insights (FMI), the global urinary tract infection treatment market revenues will grow at a mere 2% CAGR between 2019 and 2029.

Launch of New Antibiotics for Bacterial Infections to Sustain Revenues

Increase in the number of research and development initiatives for the developing novel therapeutics has led to the launch of new drugs into the urinary tract infection treatment market. Manufacturers are currently focusing on expanding their pipeline portfolio for the treatment of bacterial infections. Moreover, regulatory bodies such as FDA have accelerated the approval process of drugs.

Recently, in August 2018, Melinta Therapeutics announced the launch of Vabomere (meropenem and vaborbactam) for patients who require treatment for complicated urinary tract infection. Similarly, one more drug has been approved by FDA in June 2018, Zemdri by Achaogen, Inc., for the treatment of adults suffering from Complicated Urinary Tract Infection (cUTI). Increase in the launch and approval of novel therapeutics for the treatment of bacterial infections is expected to contribute to the growth of the urinary tract infection treatment market.

Request a Sample Report with Table of Contents and Figures: https://www.futuremarketinsights.com/reports/sample/rep-gb-1340

Quinolones, the broad spectrum antibiotics effective against a wide range of bacterial disease, have bactericidal activity that enables them to penetrate deep into the tissue. Their excellent bioavailability is a plus point. In addition, they have favourable tolerability and safety profile. Moreover, they have significant antimicrobial activity. Thus, quinolones are most preferred for the treatment of urinary tract infection. Some of the widely used quinolones for the prevention of bacterial infection include ciprofloxacin (Cipro), ofloxacin (Floxin), norfloxacin (Noroxin), and others. Quinolones are mostly favored over trimethoprim-sulfamethoxazole (TMP-SMX) for the treatment of uncomplicated urinary tract infections owing to the increasing resistance of bacteria towards antibiotics such as trimethoprim-sulfamethoxazole, beta lactam antibiotics, and others

Preview analysis of Urinary Tract Infection (UTI) Treatment Market: Sustained Use of Urinary Catheters Offering the Necessary Push: Global Industry Analysis 2014-2018 and Opportunity Assessment 2019-2029: https://www.futuremarketinsights.com/reports/urinary-tract-infections-market

Europe Remains Major Revenue Contributor

Europe holds a considerable revenue share in the UTI treatment market. The rising prevalence of urinary tract infection among the population and increasing hospital visits are among factors that are likely to propel the growth of the urinary tract infection treatment market. It is estimated that the urinary tract infection treatment market will create an incremental $ opportunity worth nearly US$ 9 Mn between 2019 and 2029. Quinolones is anticipated to boost the growth of the urinary tract infection treatment market owing to the increasing prescription and high effectivity as antimicrobial antibiotics.

Demand from Retail Pharmacies to Register High Growth

The global urinary tract infection treatment market has been segmented on the basis of drug class, indication, and distribution channel. On the basis of drug class, the urinary tract infection treatment market has been segmented into Penicillin & Combinations, Quinolones, Cephalosporin, Aminoglycoside Antibiotics, Sulphonamides (Sulfamethoxazole +Trimethoprim), Azoles and Amphotericin B, Tetracycline (Doxycycline), Nitrofurans (Nitrofurantoin), and others. In terms of revenue, the quinolones segment is expected to hold a major share of the urinary tract infection treatment market during the forecast period since it is widely prescribed and has proven to be safe and effective for antimicrobial